Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease

[1]  R. Steiner,et al.  Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP) , 2013, Journal of Inherited Metabolic Disease.

[2]  G. Węgrzyn,et al.  Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease. , 2012, Gene.

[3]  A. Węgrzyn Gene expression‐targeted isoflavone therapy , 2012, IUBMB life.

[4]  S. Stockler,et al.  Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients , 2012, Journal of Inherited Metabolic Disease.

[5]  G. Węgrzyn,et al.  Genistein in Sanfilippo disease: A randomized controlled crossover trial , 2012, Annals of neurology.

[6]  T. Braulke,et al.  Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome , 2011, American journal of medical genetics. Part A.

[7]  M. O'Callaghan,et al.  Genistein supplementation in patients affected by Sanfilippo disease , 2011, Journal of Inherited Metabolic Disease.

[8]  E. Glamuzina,et al.  Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points , 2011, Journal of Inherited Metabolic Disease.

[9]  S. Raoul,et al.  Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Zafeiriou,et al.  Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece , 2011, American journal of medical genetics. Part A.

[11]  J. Petty,et al.  Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases , 2010, Journal of Inherited Metabolic Disease.

[12]  R. Wevers,et al.  Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.

[13]  M. Elleder,et al.  The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations , 2010, Journal of Inherited Metabolic Disease.

[14]  H. Omran,et al.  Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations b , 2010, Human mutation.

[15]  Carmela Di Domenico,et al.  Serum MIP-1 α level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice , 2010, Journal of Inherited Metabolic Disease.

[16]  H. Azzouz,et al.  Incidence of mucopolysaccharidoses in Tunisia. , 2009, La Tunisie medicale.

[17]  A. Pshezhetsky,et al.  Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl‐CoA: α‐glucosaminide N‐acetyltransferase (HGSNAT) gene , 2009, Human mutation.

[18]  L. Kudo,et al.  Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy , 2009, Proceedings of the National Academy of Sciences.

[19]  G. Węgrzyn,et al.  Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. , 2008, Current therapeutic research, clinical and experimental.

[20]  A. Pshezhetsky,et al.  Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. , 2008, Molecular genetics and metabolism.

[21]  J. Hopwood,et al.  Functional analysis of the HGSNAT gene in patients with mucopolysaccharidosis IIIC (Sanfilippo C Syndrome) , 2007, Human mutation.

[22]  S. McCandless,et al.  A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). , 2007, Molecular genetics and metabolism.

[23]  J. Wittes,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.

[24]  F. Krummenauer,et al.  Cumulative incidence rates of the mucopolysaccharidoses in Germany , 2005, Journal of Inherited Metabolic Disease.

[25]  N. Cengiz,et al.  Glycosaminoglycans in childhood urinary tract infections , 2005, Pediatric Nephrology.

[26]  J. E. Wraith,et al.  The first 5years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I , 2005, Expert opinion on pharmacotherapy.

[27]  Joseph Muenzer,et al.  Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). , 2004, The Journal of pediatrics.

[28]  O. Amaral,et al.  Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.

[29]  J. Hopwood,et al.  Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications , 2001, Human mutation.

[30]  J. Hopwood,et al.  Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. , 2001, Molecular genetics and metabolism.

[31]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[32]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[33]  R. Wevers,et al.  Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. , 1992, Clinical chemistry.

[34]  R. Wevers,et al.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. , 1989, Clinical chemistry.

[35]  T. Perniola,et al.  Recurrent comatose state with red urine in a female infant , 1982, Journal of Inherited Metabolic Disease.

[36]  K. Figura,et al.  Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C) , 1981, Clinical genetics.

[37]  C. Epstein,et al.  Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes. , 1975, Biochemical medicine.

[38]  K. Meyer,et al.  THE FATE OF INJECTED MUCOPOLYSACCHARIDES , 1962 .

[39]  R. Wevers,et al.  UvA-DARE ( Digital Academic Repository ) Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype , 2017 .

[40]  G. Węgrzyn,et al.  The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients. , 2012, JIMD reports.

[41]  J. Hopwood Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies , 2007 .

[42]  J. Hopwood,et al.  Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes , 1999, European Journal of Human Genetics.

[43]  K. Meyer,et al.  The fate of injected mucopolysac-charides. , 1962, The Journal of clinical investigation.